RxSight, Inc.
For the period ended Mar 31, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 6, 2026
RXST$4.90+0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE LOSS (UNAUDITED)
(In thousands, except share and per share amounts)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Sales | $30,893 | $37,895 |
| Cost of sales | 7,395 | 9,566 |
| Gross profit | 23,498 | 28,329 |
| Operating expenses: | ||
| Selling, general and administrative | 31,855 | 28,636 |
| Research and development | 9,472 | 10,367 |
| Total operating expenses | 41,327 | 39,003 |
| Loss from operations | (17,829) | (10,674) |
| Other income (expense), net: | ||
| Interest expense | (3) | (6) |
| Interest and other income | 1,954 | 2,508 |
| Loss before income taxes | (15,878) | (8,172) |
| Income tax expense | 6 | 18 |
| Net loss | $(15,884) | $(8,190) |
| Other comprehensive loss | ||
| Unrealized loss on short-term investments | (120) | (157) |
| Foreign currency translation gain | — | 6 |
| Total other comprehensive loss | (120) | (151) |
| Comprehensive loss | $(16,004) | $(8,341) |
| Net loss per share: | ||
| Basic & diluted | $(0.38) | $(0.20) |
| Weighted-average shares used in computing net loss per share: | ||
| Attributable to common stock, basic & diluted | 41,306,110 | 40,509,646 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.